Align Technology stock falls after mixed Q2 results and guidance miss

Published on 09/04/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Align Technology stock is under pressure as investors digest Q2 2026 results with modest revenue growth but softer guidance, while the share price remains well below its recent levels.

Börsenhändler im NASDAQ-Saal mit Medtech-Kurscharts auf Bildschirmen — Align Technology Inc. Börsen-Editorial NASDAQ Handelssaal mit steigenden Medtech-Aktienkursen und Händlern US0162551016, Illustration mit AI erstellt.

Align Technology stock (ISIN US0162551016) remains under pressure after the company reported Q2 2026 results with revenue of USD 1.06 billion, up 4.3% year on year, but issued guidance that came in below analysts' expectations, according to a detailed earnings overview published on September 3, 2026.

Q2 2026 numbers disappoint the market

According to an earnings analysis on a major financial portal, Align Technology generated Q2 2026 revenue of USD 1.06 billion, representing a 4.3% increase compared with the same quarter of the previous year.

The same analysis notes that Align Technology's earnings per share in Q2 2026 beat analyst estimates, while revenue guidance for the next quarter was slightly below consensus expectations, leading to a cautious market reaction.

Stock reaction and valuation context

The earnings commentary highlights that the market reacted negatively to the Q2 2026 figures and guidance, as Align Technology stock has fallen 12.2% since the report and is quoted at around USD 158.04 in recent trading, significantly below levels seen before the publication of the results.

For investors, this move indicates a clear disconnect between the modest top-line growth of 4.3% in Q2 2026 and the market's expectations for stronger momentum, especially given that guidance for the following quarter did not match the prior consensus.

Go deeper

More on Align Technology fundamentals

Investors can explore additional news and filings on Align Technology to better understand how the company plans to balance growth investments with profitability after its mixed Q2 2026 report.

All news on US0162551016 Investor Relations

Invisalign remains the core growth driver

Align Technology's core product line is the Invisalign clear aligner system, which has transformed orthodontic treatment by offering removable, nearly invisible aligners instead of traditional braces.

Recent company communications highlight that the Invisalign portfolio, combined with the iTero intraoral scanner platform, remains central to driving revenue growth and case volumes worldwide, particularly in adolescent orthodontics and adult cosmetic treatments.

Stock remains below recent highs

As of early September 2026, Align Technology stock trades around USD 158, reflecting a notable decline of about 12% since the Q2 2026 earnings release, and keeping the shares well below the more elevated levels seen before the latest guidance update.